Compare iShares MSCI Australia ETF (EWA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Koninklijke Philips NV — how do they compare? iShares MSCI Australia ETF trades at $28.62 (market cap $1.17B), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 20.1× iShares MSCI Australia ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Koninklijke Philips NV for 84 Days on average.
| EWA | PHG | |
|---|---|---|
Market Cap | $1.17B | $23.52B |
Volume | 2,121,231 | 1,635,069 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $32.91 |
52-Week Low | $24.95 | $23.81 |
Typical Hold Time | 61 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, showing no change over the past 24 hours. Technical indicators are predominantly bearish, with moving averages signaling a sell and oscillators neutral. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns, though some analysts see upside potential tied to commodity exposure.
The outlook is mixed; EWA offers exposure to Australia's commodity-driven economy with potential for gains if raw material prices rise, but faces headwinds from inflation and monetary policy tightening. Key risks include economic sensitivity to global demand and market volatility. Analyst sentiment is divided, with some targeting over 20% upside.
PHG trades at $24.30, up 0.87% with a bearish technical signal despite three consecutive quarterly earnings beats. The company shows improving fundamentals with net income turning positive at $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care.
While analyst consensus leans Hold (63.64%), the improving profitability trajectory and reasonable valuation (P/E 18.94) present opportunity, though technical weakness and competitive healthcare market risks require monitoring. The stock faces resistance near $25 with support at $24, with institutional ownership showing mixed signals through recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
